References
- Hughes L. E. Classification of benign breast disorders. Br. Med. Bull. 1991; 47: 251–7
- Working Party for the Nordic Cancer Union. Breast-cancer etiology. Int. J. Cancer, Suppl. 1990; 5: 22–39
- Levi F., Randimbison L., Te V. C., La Vecchia C. Incidence of breast cancer in women with fibroadenoma. Int. J. Cancer 1994; 57: 681–3
- Sitruk-Ware R., Sterkers N., Mauvais-Jarvis P. Benign breast disease. I. Hormonal investigation. Obstet. Gynecol. 1979; 53: 457–60
- Kumar S., Mansel R. E., Hughes L. E., Wood-head J. S., Edwards C. A., Scanlon M. P., Newcombe R. G. Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 1984; 53: 1311–15
- Dogliotti L., Fagginolo R., Ferusso A., Orlandi F., Sandrucci S., Tibo A., Angeli A. Prolactin and thyrotropin response to thyrotropin-releasing hormone in premenopausal women with fibrocystic breast disease. Horm. Res. 1985; 21: 137–44
- Peters F., Pichardt C. R., Breckwoldt M. Thyroid hormones in benign breast disease: normalization of exaggerated prolactin responsiveness to thyrotropin-releasing hormone. Cancer 1985; 56: 1082–5
- Dabre P. D. Steroids and steroid receptors in growth control of cultured breast cancer cells. Int. J. Cancer 1990; Suppl. 5: 5–21
- Grossman C. J. Interactions between the gonadal steroids and the immune system. Science 1985; 227: 257–61
- Daynes R. A., Meikle A. W., Araneo B. A. Locally active steroid hormones may facilitate compartmentalization of immunity by regulating the types of lymphokines produced by helper T cells. Res. Immunol. 1991; 142: 40–5
- Seaman W. E., Blackman M. A., Ginhart T. D., Roubinian J. R., Loeb J. M., Talal N. b˜-Estradiol reduces natural killer cells in mice. J. Immunol 1978; 121: 2193–8
- Hanna N., Schneider M. Enhancement of tumor metastasis and suppression of natural killer cell activity by b˜-estradiol treatment. J. Immunol 1983; 130: 974–80
- Storkus W. J., Dawson J. R. Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. Crit. Rev. Immunol 1991; 10: 393–416
- Wiltrout R. H. Functions of the Natural Immune System. , C. W. Reynolds. Plenum Publ. Corp., New York 1989
- Malejczyk J., Majewski S., Jablonska S., Rogozinski T. T., Orth G. Abrogated NK-cell lysis of human papillomavirus (HPV)-16-bearing keratinocytes in patients with precancerous and cancerous HPV-induced anogenital lesions. Int. J. Cancer 1989; 43: 209–14
- Pross H. F., Sterns E., MacGillis D. R. Natural killer cell activity in women at “high risk” for breast cancer with and without benign breast syndrome. Int. J. Cancer 1984; 34: 303–8
- Robinson E., Rubin D., Mekori T., Segal R., Pollack S. in vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer. Cancer Immunol Immunother. 1993; 37: 209–12
- Garzetti G. G., Ciavattini A., Provinciali M., Fabris N., Cignitti M., Romanini C. Natural killer cell activity in endometriosis: correlation between serum estradiol levels and cytotoxicity. Obstet. Gynecol 1993; 81: 665–8
- Roszkowski P. I., Hyc A., Malejczyk J. Natural killer cell activity in patients with ovarian tumors and uterine myomas. Eur. J. Gynaecol. Oncol 1993; 14(Suppl)114–17, )
- Berry J., Green B. J., Matheson D. S. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur. J. Cancer Clin. Oncol 1987; 23: 517–20
- Rothstein S., Blomgren H., Petrini B., Wasser-man J., von Stedingk L. V. Influence of adjuvant tamoxifen on blood lymphocytes. Breast Cancer Res. Treat. 1988; 12: 75–9
- Berry J., Green B. J., Matheson D. S. Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminogluthemide. Cancer Immunol. Immunother. 1987; 24: 72–5
- Mannel D. N., Falk W., Yron I. Inhibition of murine cytotoxic T cell responses by progesterone. Immunol. Lett. 1990; 26: 89–94